NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Friday as it is currently trading at $25.74, above its previous 52-week high of $25.45 with 237,097 shares traded as of 9:48 a.m. ET. Average volume has been 812,200 shares over the past 30 days.

Myriad has a market cap of $2.1 billion and is part of the services sector and diversified services industry. Shares are up 11.1% year to date as of the close of trading on Thursday.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine products. The company has a P/E ratio of 18.6, above the average diversified services industry P/E ratio of 18.4 and above the S&P 500 P/E ratio of 17.7.
  • Practice your MYGN trading strategies and win cash in our stock game.

TheStreet Ratings rates Myriad as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Myriad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments